EDSA - Edesa receives FDA approval to initiate Covid studies in the US

Edesa Biotech ([[EDSA]] +3.1%), receives FDA clearance to begin the Phase 2 portion of its Phase 2/3 clinical study of its investigational drug, EB05, for treatment of Covid-19.EB05 is an experimental monoclonal antibody that the company believes could regulate the overactive immune response associated with Acute Respiratory Distress Syndrome pr ARDS - the leading cause of death in COVID-19 patients.The company has begun the site initiation process at U.S. hospitals.Press Release

For further details see:

Edesa receives FDA approval to initiate Covid studies in the US